Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech clinical trial

Immunovant IMVT-1402 CLE Trial Miss

Analysis based on 7 articles · First reported Sep 23, 2026 · Last updated Sep 23, 2026

Sentiment
-10
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The failure of IMVT-1402 in cutaneous lupus erythematosus removes a near-term indication from Immunovant's pipeline and may pressure shares of both Immunovant and its majority owner Roivant, though the company's decision to halt only this program limits the damage. Because other IMVT-1402 development timelines remain on track, the market impact is likely contained to modest negative sentiment around the FcRn franchise rather than a broad repricing of the pipeline.

biotechnology pharmaceuticals

Immunovant announced topline results from Period 1 of its proof-of-concept trial evaluating IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE). The randomized, double-blind, placebo-controlled global study enrolled 57 adult patients who were randomized to IMVT-1402 or placebo for a 12-week treatment period. The trial did not achieve statistical significance on its primary endpoint of percent change from baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) score at Week 12. Numerical trends favoring IMVT-1402 over placebo were observed across multiple endpoints, and patients who achieved deeper IgG reductions from baseline were more likely to achieve improved clinical responses. IMVT-1402 demonstrated a favorable safety and tolerability profile consistent with prior studies. However, due to the competitive landscape and the clinical results observed, Immunovant plans to stop development of IMVT-1402 in CLE, as the study did not meet its internal bar. Immunovant remains focused on advancing IMVT-1402 across other autoimmune indications including Graves' disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and Sjogren's disease, and stated all other clinical development timelines remain on track. Roivant, Immunovant's majority owner, announced the results. CEO Eric Venker thanked patients, investigators, and clinical site teams.

85 Immunovant reported topline results
70 Roivant Sciences announced topline results
stock
Immunovant is the central actor, reporting failed primary endpoint results for IMVT-1402 in CLE and deciding to stop development in that indication. The setback removes a pipeline opportunity but leaves other autoimmune programs on track.
Importance 100.0 Sentiment -35.0
priv
Roivant, as Immunovant's majority owner, announced the topline results and shares in the pipeline setback. Its exposure is indirect but its equity stake and pipeline narrative are affected.
Importance 70.0 Sentiment -25.0
per
Immunovant CEO Eric Venker commented on the study results, thanking patients and investigators and framing the outcome as advancing understanding of FcRn inhibition. His role is communicative rather than operational in this event.
Importance 20.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.